Orthopedic devices are used to treat the disorders and injuries of the musculoskeletal system of human body. Orthobiologics are biomaterials used in orthopedic surgery as an adjunct to faster fusion and healing of the bone. Soft Tissue Biologics are used in surgical procedures to replace, reinforce, or repair tendons or ligaments that have been torn or damaged in the human body. GlobalData uses proprietary data and analytics to provide a comprehensive report on the soft tissue biologics market in Sweden. Buy the latest report here.
In 2022, GlobalData’s Market Model methodology determined that the leading player in the soft tissue biologics market in Sweden was AlloSource followed by Arthrex, ConMed, LifeNet Health, Smith & Nephew, Wright Medical Group and Zimmer Biomet.
Understanding market size can be crucial to evaluate opportunities and make informed decisions about market entry and exit. Medical device companies can identify attractive segments in respective markets as well as develop marketing strategies based on forecasts for those segments.
This Soft Tissue Biologics market focuses on the repair of the anterior cruciate ligament (ACL), posterior cruciate ligament (PCL), rotator cuff, and Achilles’s tendon. Other indications include medial collateral ligament (MCL), lateral collateral ligament (LCL), medial patellofemoral ligament (MPFL), ulnar collateral ligament (UCL), flexor tendon, and hip flexor repair. Soft Tissue Biologics can be either tendon grafts/reinforcements or tendon wrapping products. Tendon grafts or reinforcements are meant to provide structural aid to or replacement of the damaged tendon in order to restore normal function. Tendon Wrapping is a form of surgical tendon repair where a small sheet of tissue that acts as a physical barrier between the repair site and the surrounding space, providing a low friction environment for the tendon to heal and operate within.
The soft tissue biologics market in Sweden can expand or contract due to a variety of reasons including population demographics, disease incidence and prevalence, macroeconomic issues, and geopolitical considerations. Disruption to a market could be caused by a sudden, unexpected change in these factors, but it could also be driven by changes in clinical practice, leading to a change in diagnosis or treatment of patients, as part of a process to generally improve medical practice.
For the latest analysis of the market size soft tissue biologics in Sweden, buy the report here.